Alzchem Reports Continued Growth in H1 2026

Alzchem Group AG, a global player in specialty chemicals, has announced a successful first half of 2026, reporting a 6% increase in sales to EUR 303.9 million. The company's EBITDA showed a notable 14% rise to EUR 64.5 million, marking a positive margin growth from 19.6% to 21.2%.

The sales boost is attributed to higher volumes and improved pricing. The Specialty Chemicals segment saw a significant 10% sales increase, driven by strong performance in Human Nutrition and Defense sectors. Alzchem also reported stability in its Basics & Intermediates segment, despite facing industry challenges.

Strategic advances include launching a new nitroguanidine plant in Germany and expanding creatine production. With a fresh financing agreement in place, Alzchem expects continued growth for the remainder of 2026.